106 related articles for article (PubMed ID: 8261437)
21. Rituximab-based treatments in Waldenström's macroglobulinemia.
Dimopoulos MA; Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Tassidou A; Terpos E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):59-61. PubMed ID: 19362975
[TBL] [Abstract][Full Text] [Related]
22. A new tubulin polymerization inhibitor, auristatin PE, induces tumor regression in a human Waldenstrom's macroglobulinemia xenograft model.
Mohammad RM; Limvarapuss C; Wall NR; Hamdy N; Beck FW; Pettit GR; Al-Katib A
Int J Oncol; 1999 Aug; 15(2):367-72. PubMed ID: 10402249
[TBL] [Abstract][Full Text] [Related]
23. Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model.
Plum SM; Hanson AD; Volker KM; Vu HA; Sim BK; Fogler WE; Fortier AH
Clin Cancer Res; 2003 Oct; 9(12):4619-26. PubMed ID: 14555538
[TBL] [Abstract][Full Text] [Related]
24. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
25. Establishment of an animal model for Waldenström's macroglobulinemia.
Tsingotjidou AS; Emmanouilides CE; Siotou E; Poutahidis T; Xagorari A; Loukopoulos P; Sotiropoulos D; Bekiari C; Doulberis M; Givissis P; Fassas A; Anagnostopoulos A
Exp Hematol; 2009 Apr; 37(4):469-76. PubMed ID: 19302921
[TBL] [Abstract][Full Text] [Related]
26. Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine.
Mohammad RM; Limvarapuss C; Hamdy N; Dutcher BS; Beck FW; Wall NR; Al-Katib AM
Int J Oncol; 1999 May; 14(5):945-50. PubMed ID: 10200346
[TBL] [Abstract][Full Text] [Related]
27. Differential effects of bryostatin 1 on human non-Hodgkin's B-lymphoma cell lines.
Mohammad RM; al-Katib A; Pettit GR; Sensenbrenner LL
Leuk Res; 1993 Jan; 17(1):1-8. PubMed ID: 8429674
[TBL] [Abstract][Full Text] [Related]
28. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.
Mohammad RM; Goustin AS; Aboukameel A; Chen B; Banerjee S; Wang G; Nikolovska-Coleska Z; Wang S; Al-Katib A
Clin Cancer Res; 2007 Apr; 13(7):2226-35. PubMed ID: 17404107
[TBL] [Abstract][Full Text] [Related]
29. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.
Al-Katib AM; Aboukameel A; Mohammad R; Bissery MC; Zuany-Amorim C
Clin Cancer Res; 2009 Jun; 15(12):4038-45. PubMed ID: 19509168
[TBL] [Abstract][Full Text] [Related]
30. Role for high-dose therapy with autologous hematopoietic stem cell support in Waldenstrom's macroglobulinemia.
Munshi NC; Barlogie B
Semin Oncol; 2003 Apr; 30(2):282-5. PubMed ID: 12720153
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice.
Papadopoulou MV; Ji M; Ji X; Bloomer WD; Hollingshead MG
Cancer Chemother Pharmacol; 2002 Dec; 50(6):501-8. PubMed ID: 12451478
[TBL] [Abstract][Full Text] [Related]
32. Durable complete remission after chemotherapy and rituximab in a case of Waldenström's macroglobulinemia with pleuropulmonary involvement.
Capalbo S; Dargenio M; Delia M; Chiefa A; Diomede D; Napoli A; Ricco R; Liso V
Ann Hematol; 2005 Sep; 84(9):625-6. PubMed ID: 15915349
[No Abstract] [Full Text] [Related]
33. Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone.
Dimopoulos MA; Tsatalas C; Zomas A; Hamilos G; Panayiotidis P; Margaritis D; Matsouka C; Economopoulos T; Anagnostopoulos N
Semin Oncol; 2003 Apr; 30(2):265-9. PubMed ID: 12720150
[TBL] [Abstract][Full Text] [Related]
34. Propagation of Waldenström's macroglobulinemia cells in vitro and in severe combined immune deficient mice: utility as a preclinical drug screening model.
al-Katib A; Mohammad R; Hamdan M; Mohamed AN; Dan M; Smith MR
Blood; 1993 Jun; 81(11):3034-42. PubMed ID: 8499639
[TBL] [Abstract][Full Text] [Related]
35. Patterns of clinical presentation, treatment, and outcome in patients with Waldenstrom's macroglobulinemia: a two-institution study.
Björkholm M; Johansson E; Papamichael D; Celsing F; Matthews J; Lister TA; Rohatiner AZ
Semin Oncol; 2003 Apr; 30(2):226-30. PubMed ID: 12720141
[TBL] [Abstract][Full Text] [Related]
36. Stem cell transplantation (SCT) for Waldenstrom's macroglobulinemia (WM).
Anagnostopoulos A; Giralt S
Bone Marrow Transplant; 2002 Jun; 29(12):943-7. PubMed ID: 12098060
[TBL] [Abstract][Full Text] [Related]
37. Waldenström's macroglobulinemia.
Cuttner J
Cancer Invest; 1991; 9(1):107. PubMed ID: 1901510
[No Abstract] [Full Text] [Related]
38. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH
Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
[TBL] [Abstract][Full Text] [Related]
39. Autologous stem cell transplantation as part of first-line treatment of Waldenström's macroglobulinemia.
Dreger P; Schmitz N
Biol Blood Marrow Transplant; 2007 May; 13(5):623-4. PubMed ID: 17448924
[No Abstract] [Full Text] [Related]
40. Efficacy of SSG and SSG/IFNalpha2 against human prostate cancer xenograft tumors in mice: a role for direct growth inhibition in SSG anti-tumor action.
Li J; Lindner DJ; Farver C; Borden EC; Yi T
Cancer Chemother Pharmacol; 2007 Aug; 60(3):341-9. PubMed ID: 17103170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]